Enhanced T-cell expansion and high viability while maintaining early memory cell phenotype
The discovery of factors impacting the success of T-cell treatment indicates that an animal origin–free (AOF) T-cell culture medium is preferred to support robust T-cell expansion and maintain high T-cell viability and an early memory phenotype for long-term therapeutic efficacy. Gibco™ CTS™ OpTmizer™ One Serum-Free Medium (SFM) was developed to address the cell therapy industry’s need for a novel AOF T-cell medium formulation. The basal medium is a single-part formulation manufactured to strict good manufacturing practice-compliant standards.
This content was supplied by Thermo Fisher Scientific.
In this application note, Thermo Fisher Scientific (MA, USA) shows the results of evaluating the performance capabilities of CTS OpTmizer One Serum-Free Medium compared to AOF or xeno-free basal media offerings from other suppliers. The media were evaluated with cells from healthy donors, as well as cells from diseased donors from two clinical indications, acute myeloid leukemia and chronic lymphocytic leukemia. The performance criteria included activated T cell expansion, cell viability, early memory T-cell phenotypes, and CD4:CD8 ratios. Additionally, experiments were executed with healthy donor cells to assess the medium’s capability to support the transduction of activated T cells with lentivirus compared to another supplier’s medium. Transduction efficiency, transduced early memory phenotype, cell expansion and viability were evaluated as performance criteria.
